» Articles » PMID: 30201985

Risk of MGUS in Relatives of Multiple Myeloma Cases by Clinical and Tumor Characteristics

Abstract

We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband's age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005-2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5-7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9-2.9) greater than expected rates. Familial risk did not differ by proband's age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.

Citing Articles

Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma.

Raghunathachar S, Krishnamurthy K, Gopalaiah L, Abhijith D, Prashant A, Parichay S Mol Biol Rep. 2024; 51(1):972.

PMID: 39249557 DOI: 10.1007/s11033-024-09892-w.


Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes.

Tanguay M, Dagenais C, LeBlanc R, Ahmad I, Claveau J, Roy J Curr Oncol. 2023; 30(6):5214-5226.

PMID: 37366879 PMC: 10297423. DOI: 10.3390/curroncol30060396.


Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.

Vachon C, Murray J, Allmer C, Larson D, Norman A, Sinnwell J Blood Adv. 2022; 6(12):3746-3750.

PMID: 35316833 PMC: 9631569. DOI: 10.1182/bloodadvances.2021006201.


A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort.

Baak L, Frank M, Durig J, Duhrsen U, Hoffmann P, Nothen M Sci Rep. 2022; 12(1):4409.

PMID: 35292679 PMC: 8924237. DOI: 10.1038/s41598-022-08294-x.


Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.

Visram A, Vachon C, Baughn L, Larson D, Smadbeck J, Dispenzieri A Leukemia. 2021; 36(4):1058-1065.

PMID: 34764424 DOI: 10.1038/s41375-021-01454-4.


References
1.
Bizzaro N, Pasini P . Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica. 1990; 75(1):58-63. View

2.
Ogmundsdottir H, Haraldsdottirm V, Johannesson G, Olafsdottir G, Bjarnadottir K, Sigvaldason H . Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica. 2005; 90(1):66-71. View

3.
ROSENLOF R, LEMON H, Rigby P . Familial factors relating to prognosis of leukemia and lymphoma. Natl Cancer Inst Monogr. 1971; 34:283-9. View